Unbiased AI-powered news
1 stories related to this topic, newest first.
Substrate placeholder — needs reviewThe U.S. Food and Drug Administration is withdrawing approval for GlaxoSmithKline's leucovorin as a treatment for cerebral folate deficiency, a rare brain disorder. GSK stated that the withdrawal was anticipated as part of the original approval plan. The disorder involves symptom…